Use of Adipose-Derived Cellular Stromal Vascular Fraction (AD-cSVF) Parenterally in Post-Concussion Injuries and Traumatic Brain Injuries (TBI) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2021

ABSTRACT

Concussion is the most common type of brain injury throughout life. Study is seeking improvement of long-term residua following adolescent and adult post-traumatic injuries often associated with contact sports and accidental causes. Typically defined as reversible head injury with temporary loss of brain function. Symptoms range from physical, cognitive, pain (headache) and emotional signs consistent with TBI and Post-Traumatic Stress Syndrome. Use of AD-cSVF parenteral delivery to encourage repair of damage and decreased function following concussion, particularly in contact, repetitive sports injuries. Range of damage is measured in Grade I-III according to graduated severity. Unfortunately, less information is available about repetitive concussions and the long-term health issues. Detailed Description Concussion Syndrome (CS) and TBI are common injuries producing temporary and long-term damage to impact brain function. Symptoms are sometimes transient, sometimes long-term depending on severity and/or repetitive damage. Signs varying from recurrent headaches, mental fog, emotional changes to physical signs of loss of consciousness, amnesia to behavioral change (irritability, loss of concentration ability, etc.), cognitive impairment (slow reaction times, memory loss), and recurring sleep disturbances. Common causes include sports injuries, automobile accidents, falls, blunt trauma to head, and explosive/blast injuries from production of acceleration injuries Treatment often involves monitoring, physical rest, limiting cognitive activities (such as computing, video games, texting, and studying). Most often a single episode usually resolve or improve (particularly in recurring headaches) within 3-4 weeks. It is estimated that >6/1000 occurrence rate apply. Repetitive injuries seem to make the person more susceptible to additional damage, particularly with injury precedes resolution of an earlier damage. There appears also to make persons to require a lesser impact to produce the same degree of severity. It is becoming more recognized that repeated concussions increase the risks in later life for dementia, Parkinson's and severe depressions. Most serious signs to evaluate are loss of consciousness, seizures, worsening headache, diplopia/pupil changes, loss of recognition, vomiting, focal neurological problems, and change of personality. There is no consensus definition of concussion or TBI. Most concussions are considered in the mild TBI (mTBI) group, and are rarely demonstrate structural brain damage when in the acute to subacute state. Late brain MRI changes are difficult to clearly point to or identify the specific areas of presumed damage. This study is intended to examine safety and efficacy of parenteral introduction of AD-cSVF in cases of CS and TBI, and categorically examine the outcomes according to the elapsed time from original concussive event. No delineation of those having recurrent damage and injuries are made within this study. More... »

URL

https://clinicaltrials.gov/show/NCT02959294

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3468", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Concussion is the most common type of brain injury throughout life. Study is seeking improvement of long-term residua following adolescent and adult post-traumatic injuries often associated with contact sports and accidental causes. Typically defined as reversible head injury with temporary loss of brain function. Symptoms range from physical, cognitive, pain (headache) and emotional signs consistent with TBI and Post-Traumatic Stress Syndrome. Use of AD-cSVF parenteral delivery to encourage repair of damage and decreased function following concussion, particularly in contact, repetitive sports injuries. Range of damage is measured in Grade I-III according to graduated severity. Unfortunately, less information is available about repetitive concussions and the long-term health issues.\n\nDetailed Description\nConcussion Syndrome (CS) and TBI are common injuries producing temporary and long-term damage to impact brain function. Symptoms are sometimes transient, sometimes long-term depending on severity and/or repetitive damage. Signs varying from recurrent headaches, mental fog, emotional changes to physical signs of loss of consciousness, amnesia to behavioral change (irritability, loss of concentration ability, etc.), cognitive impairment (slow reaction times, memory loss), and recurring sleep disturbances. Common causes include sports injuries, automobile accidents, falls, blunt trauma to head, and explosive/blast injuries from production of acceleration injuries Treatment often involves monitoring, physical rest, limiting cognitive activities (such as computing, video games, texting, and studying). Most often a single episode usually resolve or improve (particularly in recurring headaches) within 3-4 weeks. It is estimated that >6/1000 occurrence rate apply. Repetitive injuries seem to make the person more susceptible to additional damage, particularly with injury precedes resolution of an earlier damage. There appears also to make persons to require a lesser impact to produce the same degree of severity. It is becoming more recognized that repeated concussions increase the risks in later life for dementia, Parkinson's and severe depressions. Most serious signs to evaluate are loss of consciousness, seizures, worsening headache, diplopia/pupil changes, loss of recognition, vomiting, focal neurological problems, and change of personality. There is no consensus definition of concussion or TBI. Most concussions are considered in the mild TBI (mTBI) group, and are rarely demonstrate structural brain damage when in the acute to subacute state. Late brain MRI changes are difficult to clearly point to or identify the specific areas of presumed damage. This study is intended to examine safety and efficacy of parenteral introduction of AD-cSVF in cases of CS and TBI, and categorically examine the outcomes according to the elapsed time from original concussive event. No delineation of those having recurrent damage and injuries are made within this study.", 
    "endDate": "2021-11-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02959294", 
    "keywords": [
      "stromal vascular fraction", 
      "AD", 
      "concussion", 
      "Brain Injury", 
      "common type", 
      "life", 
      "improvement", 
      "long term", 
      "traumatic injury", 
      "sport", 
      "head", 
      "brain function", 
      "symptom", 
      "pain", 
      "headache", 
      "sign", 
      "post-traumatic stress", 
      "delivery", 
      "repair", 
      "damage", 
      "decreased function", 
      "sport injury", 
      "grade", 
      "severity", 
      "less information", 
      "long-term health", 
      "common injury", 
      "long-term damage", 
      "emotional change", 
      "consciousness", 
      "amnesia", 
      "behavioral change", 
      "irritability", 
      "cognitive impairment", 
      "Reaction Time", 
      "Memory Disorder", 
      "disturbance", 
      "automobile accident", 
      "Wound and Injury", 
      "acceleration", 
      "rest", 
      "cognitive activity", 
      "video game", 
      "Text Messaging", 
      "single episode", 
      "occurrence rate", 
      "additional damage", 
      "resolution", 
      "less impact", 
      "same degree", 
      "risk", 
      "late life", 
      "dementia", 
      "Parkinson's", 
      "severe depression", 
      "seizure", 
      "recognition", 
      "vomiting", 
      "neurological problem", 
      "personality", 
      "definition", 
      "traumatic brain", 
      "brain damage", 
      "subacute", 
      "MRI change", 
      "specific area", 
      "efficacy", 
      "introduction", 
      "elapsed time", 
      "delineation"
    ], 
    "name": "Use of Adipose-Derived Cellular Stromal Vascular Fraction (AD-cSVF) Parenterally in Post-Concussion Injuries and Traumatic Brain Injuries (TBI)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02959294"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00022.json", 
    "startDate": "2016-11-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1176/appi.psy.46.3.195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001396849"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10484-008-9056-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005229540", 
          "https://doi.org/10.1007/s10484-008-9056-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006123-200009000-00027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007881562"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(08)70164-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012072070"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00001199-200609000-00001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012231697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1249/jsr.0b013e318207831d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015490408"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0278-5919(05)70059-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017566103"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1227/01.neu.0000255514.73967.90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018468360"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1249/01.mss.0000186726.18341.70", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027119331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01688638608401325", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028858491"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.emc.2007.07.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033874352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/awn347", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035033872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/neu.2008.0586", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043266834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000111872", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045388737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/aia.0b013e318078cfe7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049649325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-2000-9826", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1057405519"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/16501960410023840", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058409593"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1089/neu.2008.0461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059300742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.45.7.1253", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064373390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077325806", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02959294"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02959294'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02959294'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02959294'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02959294'


 

This table displays all metadata directly associated to this object as RDF triples.

150 TRIPLES      15 PREDICATES      105 URIs      79 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02959294 schema:about anzsrc-for:3120
2 anzsrc-for:3468
3 schema:description Concussion is the most common type of brain injury throughout life. Study is seeking improvement of long-term residua following adolescent and adult post-traumatic injuries often associated with contact sports and accidental causes. Typically defined as reversible head injury with temporary loss of brain function. Symptoms range from physical, cognitive, pain (headache) and emotional signs consistent with TBI and Post-Traumatic Stress Syndrome. Use of AD-cSVF parenteral delivery to encourage repair of damage and decreased function following concussion, particularly in contact, repetitive sports injuries. Range of damage is measured in Grade I-III according to graduated severity. Unfortunately, less information is available about repetitive concussions and the long-term health issues. Detailed Description Concussion Syndrome (CS) and TBI are common injuries producing temporary and long-term damage to impact brain function. Symptoms are sometimes transient, sometimes long-term depending on severity and/or repetitive damage. Signs varying from recurrent headaches, mental fog, emotional changes to physical signs of loss of consciousness, amnesia to behavioral change (irritability, loss of concentration ability, etc.), cognitive impairment (slow reaction times, memory loss), and recurring sleep disturbances. Common causes include sports injuries, automobile accidents, falls, blunt trauma to head, and explosive/blast injuries from production of acceleration injuries Treatment often involves monitoring, physical rest, limiting cognitive activities (such as computing, video games, texting, and studying). Most often a single episode usually resolve or improve (particularly in recurring headaches) within 3-4 weeks. It is estimated that >6/1000 occurrence rate apply. Repetitive injuries seem to make the person more susceptible to additional damage, particularly with injury precedes resolution of an earlier damage. There appears also to make persons to require a lesser impact to produce the same degree of severity. It is becoming more recognized that repeated concussions increase the risks in later life for dementia, Parkinson's and severe depressions. Most serious signs to evaluate are loss of consciousness, seizures, worsening headache, diplopia/pupil changes, loss of recognition, vomiting, focal neurological problems, and change of personality. There is no consensus definition of concussion or TBI. Most concussions are considered in the mild TBI (mTBI) group, and are rarely demonstrate structural brain damage when in the acute to subacute state. Late brain MRI changes are difficult to clearly point to or identify the specific areas of presumed damage. This study is intended to examine safety and efficacy of parenteral introduction of AD-cSVF in cases of CS and TBI, and categorically examine the outcomes according to the elapsed time from original concussive event. No delineation of those having recurrent damage and injuries are made within this study.
4 schema:endDate 2021-11-01T00:00:00Z
5 schema:keywords AD
6 Brain Injury
7 MRI change
8 Memory Disorder
9 Parkinson's
10 Reaction Time
11 Text Messaging
12 Wound and Injury
13 acceleration
14 additional damage
15 amnesia
16 automobile accident
17 behavioral change
18 brain damage
19 brain function
20 cognitive activity
21 cognitive impairment
22 common injury
23 common type
24 concussion
25 consciousness
26 damage
27 decreased function
28 definition
29 delineation
30 delivery
31 dementia
32 disturbance
33 efficacy
34 elapsed time
35 emotional change
36 grade
37 head
38 headache
39 improvement
40 introduction
41 irritability
42 late life
43 less impact
44 less information
45 life
46 long term
47 long-term damage
48 long-term health
49 neurological problem
50 occurrence rate
51 pain
52 personality
53 post-traumatic stress
54 recognition
55 repair
56 resolution
57 rest
58 risk
59 same degree
60 seizure
61 severe depression
62 severity
63 sign
64 single episode
65 specific area
66 sport
67 sport injury
68 stromal vascular fraction
69 subacute
70 symptom
71 traumatic brain
72 traumatic injury
73 video game
74 vomiting
75 schema:name Use of Adipose-Derived Cellular Stromal Vascular Fraction (AD-cSVF) Parenterally in Post-Concussion Injuries and Traumatic Brain Injuries (TBI)
76 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02959294
77 schema:sdDatePublished 2019-03-07T15:26
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N6e0cc00921b74246b9edb6e74b2264bc
80 schema:startDate 2016-11-01T00:00:00Z
81 schema:subjectOf sg:pub.10.1007/s10484-008-9056-z
82 https://app.dimensions.ai/details/publication/pub.1077325806
83 https://doi.org/10.1016/j.emc.2007.07.001
84 https://doi.org/10.1016/s0278-5919(05)70059-4
85 https://doi.org/10.1016/s1474-4422(08)70164-9
86 https://doi.org/10.1055/s-2000-9826
87 https://doi.org/10.1080/01688638608401325
88 https://doi.org/10.1080/16501960410023840
89 https://doi.org/10.1089/neu.2008.0461
90 https://doi.org/10.1089/neu.2008.0586
91 https://doi.org/10.1093/brain/awn347
92 https://doi.org/10.1097/00001199-200609000-00001
93 https://doi.org/10.1097/00006123-200009000-00027
94 https://doi.org/10.1097/aia.0b013e318078cfe7
95 https://doi.org/10.1159/000111872
96 https://doi.org/10.1176/appi.psy.46.3.195
97 https://doi.org/10.1212/wnl.45.7.1253
98 https://doi.org/10.1227/01.neu.0000255514.73967.90
99 https://doi.org/10.1249/01.mss.0000186726.18341.70
100 https://doi.org/10.1249/jsr.0b013e318207831d
101 schema:url https://clinicaltrials.gov/show/NCT02959294
102 sgo:license sg:explorer/license/
103 sgo:sdDataset clinical_trials
104 rdf:type schema:MedicalStudy
105 N6e0cc00921b74246b9edb6e74b2264bc schema:name Springer Nature - SN SciGraph project
106 rdf:type schema:Organization
107 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
108 rdf:type schema:DefinedTerm
109 anzsrc-for:3468 schema:inDefinedTermSet anzsrc-for:
110 rdf:type schema:DefinedTerm
111 sg:pub.10.1007/s10484-008-9056-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1005229540
112 https://doi.org/10.1007/s10484-008-9056-z
113 rdf:type schema:CreativeWork
114 https://app.dimensions.ai/details/publication/pub.1077325806 schema:CreativeWork
115 https://doi.org/10.1016/j.emc.2007.07.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033874352
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1016/s0278-5919(05)70059-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017566103
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1016/s1474-4422(08)70164-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012072070
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1055/s-2000-9826 schema:sameAs https://app.dimensions.ai/details/publication/pub.1057405519
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1080/01688638608401325 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028858491
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1080/16501960410023840 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058409593
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1089/neu.2008.0461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059300742
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1089/neu.2008.0586 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043266834
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1093/brain/awn347 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035033872
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1097/00001199-200609000-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012231697
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1097/00006123-200009000-00027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007881562
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1097/aia.0b013e318078cfe7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049649325
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1159/000111872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045388737
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1176/appi.psy.46.3.195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001396849
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1212/wnl.45.7.1253 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064373390
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1227/01.neu.0000255514.73967.90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018468360
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1249/01.mss.0000186726.18341.70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027119331
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1249/jsr.0b013e318207831d schema:sameAs https://app.dimensions.ai/details/publication/pub.1015490408
150 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...